Vandetanib and indwelling pleural catheter for non-small cell lung cancer with recurrent malignant pleural effusion

BACKGROUND: Non-small-cell lung cancer patients with malignant pleural effusion have a poor overall median survival (4.3 months). Vascular endothelial growth factor (VEGF) is a key regulator of pleural effusion production. It is unknown if pharmacological inhibition of VEGF signaling modifies the di...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Massarelli, Erminia, Onn, Amir, Marom, Edith M., Alden, Christine M., Liu, Diane D., Tran, Hai T., Mino, Barbara, Wistuba, Ignacio I., Faiz, Saadia A., Bashoura, Lara, Eapen, George A., Morice, Rodolfo C., Jack Lee, J., Hong, Waun K., Herbst, Roy S., Jimenez, Carlos A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160385/
https://ncbi.nlm.nih.gov/pubmed/24913066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2014.04.002
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller